Alimera sciences welcomes ophthalmic strategic consultant erin parsons to its board of directors

Atlanta, dec. 01, 2021 (globe newswire) -- alimera sciences, inc. (nasdaq: alim) (“alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of erin parsons to its board of directors. ms. parsons has more than 20 years of experience working in the ophthalmic industry overseeing scientific strategy, medical communications, advocacy development, and peer-to-peer educational programs, much of this in the retina space.
ALIM Ratings Summary
ALIM Quant Ranking